The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Ankylosing Spondylitis.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Thoracic Aortic Aneurysm.

The Fc fusion therapeutics market is estimated to be worth $15.5 billion in 2022 and is expected to grow at CAGR of 10% during the forecast period. In March 2026, Shanghai Henlius Biotech dosed the first patient in a phase 1b / 2 trial of HLX701, a next-generation SIRPα-Fc fusion protein, in combination with cetuximab and chemotherapy for advanced RAS / BRAF wild-type metastatic colorectal cancer in China.

The ocular drug delivery devices market is expected to grow from USD 964 Mn in 2025 to USD 1,098 Mn in 2026 and USD 1,616 Mn by 2030, at a CAGR of 10.1%. It is also worth highlighting that around 1.7 billion individuals worldwide are expected to lose their vision by 2050. As per the Centers for Disease Control and Prevention (CDC), loss of vision can pose an economic burden of over USD 35 billion, in terms of loss of productivity and direct costs of treatment / care. In fact, over 1,100 patents...

With nearly 300 million dry eye sufferers worldwide, dry eye represents one of the largest ophthalmic indications. The prevalence of dry eye syndrome primarily increases with age, and has an estimated incidence of 15% in persons over the age of 65 years. In fact, tn the US alone, the economic burden of dry eye totals USD 3.84 billion in direct annual health care costs. After including the indirect costs of lost productivity, the societal burden of dry eye rises to USD 55.4 billion annually in t...

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Generalized Anxiety Disorder.

The biospecimen procurement market is estimated to be worth $52 million in 2021 and is expected to grow at CAGR of 16% during the forecast period. Over the last few decades, the field of biospecimen research has witnessed significant technological advancements resulting in the procurement of high quality biospecimens for molecular research purposes. This shift is evident from the increase in partnership activity focused on expanding the existing capabilities of service providers and offering bio...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The global progressive supranuclear palsy (PSP) market, valued at USD 231 million in 2025, is projected to reach USD 313 million in 2026 and USD 492 million by 2030, with a 11.9% CAGR during the forecast period, 2026 to 2030. One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Progressive Supranuclear Palsy, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecaste...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The clinical trial design market is estimated to be worth $441 million in 2021 and is expected to grow at CAGR of 8% during the forecast period. Clinical trials form an integral part of the overall drug development process, as they enable both innovators and regulators to assess the safety and efficacy of a drug candidate. The critical role of these studies can also be verified from the fact that they capture around 50% share of the total time and cost related investments made for the developmen...

Bevacizumab is VEGF-A targeting, humanized monoclonal antibody-based therapeutic developed by Genentech and Roche. It was the first angiogenesis inhibitor drug to be approved by the US FDA. Avastin

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

TThis report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The HER2 receptor is a well characterized biomarker that is overexpressed in a number of types of cancer cells, including 25% to 30% of breast cancers. It was discovered and developed by scientists at Genentech (a fully own subsidiary of Roche), in collaboration with the University of California, Los Angeles; the first clinical trial of the drug was initiated in 1992. Moreover, in combination with certain other chemotherapies (such as paclitaxel), the drug has been shown to significantly improve...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The global RNA targeted therapeutics market size, valued at USD 1,764 million in 2025, is projected to reach USD 2,245 million in 2026 and USD 8,276 million by 2030, representing a CAGR of 38.6% during the forecast period. In recent past, RNA’s limitless potential as a target for small molecules, against a wide range of indications (both oncological and non-oncological), has been recognized. Specifically, a variety of small molecules that affect RNA function have been discovered. Further, many...